Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Lin, Zhong Zhe ^a,b   Shau, Wen Yi ^c   Hsu, Chiun ^a,b   Shao, Yu Yun ^a,b   Yeh, Yi Chun ^a   Kuo, Raymond Nien Chen ^a,d,e   Hsu, Chih Hung ^a,b   Yang, James Chih Hsin ^a,b   Cheng, Ann Lii ^a,b   Lai, Mei Shu ^a,d,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Center for Drug Evaluation   (Taiwan)

^d Taiwan Cancer Registry   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

ADULT; AGE; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; POPULATION RESEARCH; RADIOFREQUENCY ABLATION; RISK REDUCTION; SEX DIFFERENCE; TAIWAN; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION; INTRADERMAL DRUG ADMINISTRATION; LIVER NEOPLASMS;

ADMINISTRATION, CUTANEOUS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COHORT STUDIES; ETHANOL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TAIWAN; TREATMENT OUTCOME;

EID: 84893182239     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080276     Document Type: Article

References (34)

1. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32: S66-S81. doi:10.1093/jjco/hye138. PubMed: 11959880.
2. El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35: S72-S78. doi: 10.1097/00004836-200211002-00002. PubMed: 12394209.
3. Befeler AS, Di Bisceglie AM (2002) Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122: 1609-1619. doi:10.1053/gast.2002.33411. PubMed: 12016426. (Pubitemid 34533556)
4. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55: 74-108. doi:10.3322/canjclin.55.2.74. PubMed: 15761078.
5. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J (1995) Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221: 291-298. doi:10.1097/00000658-199503000-00012. PubMed: 7717783.
6. Poon RT, Fan ST, Tsang FH, Wong J (2002) Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 235: 466-486. doi:10.1097/00000658-200204000-00004. PubMed: 11923602. (Pubitemid 34258345)
7. Livraghi T (2001) Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Hepatogastroenterology 48: 20-24. PubMed: 11268965.
8. Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P et al. (1995) Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1: 73-81. PubMed: 9166457.
9. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48: S20-S37. doi:10.1016/S0168- 8278(08)60049-5. PubMed: 18304676.
10. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G et al. (2010) Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 52: 380-388. doi:10.1016/S0168-8278(10)60984-1. PubMed: 20149473.
11. Clark TW (2007) Chemical ablation of liver cancer. Tech Vasc Interv Radiol 10: 58-63. doi:10.1053/j.tvir.2007.08.004. PubMed: 17980319.
12. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M et al. (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40: 1352-1360. doi:10.1002/hep.20465. PubMed: 15565564. (Pubitemid 39657009)
13. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917. doi:10.1016/S0140-6736(03)14964-1. PubMed: 14667750. (Pubitemid 37518510)
14. Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022. Available: http://www.aasld.org/practiceguidelines/Documents/ Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf. Accessed 20 July 2012. doi:10.1002/hep.24199. PubMed: 21374666.
15. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P et al. (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation vs percutaneous ethanol injection. Radiology 228: 235-240. doi:10.1148/radiol.2281020718. PubMed: 12759473. (Pubitemid 36736097)
16. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 127: 1714-1723. doi:10.1053/j.gastro.2004.09. 003. PubMed: 15578509.
17. Shiina S, Teratani T, Obi S, Sato S, Tateishi R et al. (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130. doi:10.1053/j.gastro.2005.04.009. PubMed: 16012942. (Pubitemid 41002049)
18. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54: 1151-1156. doi:10.1136/gut.2004.045203. PubMed: 16009687.
19. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G et al. (2008) Radiofrequency ablation vs ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 43: 727-735. doi:10.1080/00365520701885481. PubMed: 18569991. (Pubitemid 351868714)
20. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M (2009) Radiofrequency thermal ablation versus percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104: 514-524. doi:10.1038/ajg.2008.80. PubMed: 19174803.
21. Cho YK, Kim JK, Kim MY, Rhim H, Han JK (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49: 453-459. doi:10.1002/hep.22648. PubMed: 19065676.
22. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35: 421-430. doi:10.1016/S0168- 8278(01)00130-1. PubMed: 11592607. (Pubitemid 32844200)
23. Tateishi R, Shiina S, Teratani T, Obi S, Sato S et al. (2005) Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103: 1201-1209. doi:10.1002/cncr.20892. PubMed: 15690326. (Pubitemid 40328091)
24. Parkin DM, Whelan SL, Ferlay J, Teppo L, International Agency for Research on Cancer et al. (2005) Cancer Incidence in Five Continents. WHO Press, Volume VIII.
25. Chiang CJ, Chen YC, Chen CJ, You SL, Lai MS (2010) Cancer Trends in Taiwan. Jpn J Clin Oncol 40: 897-904. doi:10.1093/jjco/hyq057. PubMed: 20495192.
26. Taiwan Cancer Registry. Available: http://tcr.cph.ntu.edu.tw/main.php? Page=N1. Accessed 20 July 2012
27. National Health Insurance in Taiwan 2010ureau of National Health Insurance, Department of Health, Taiwan R.O.C., 2010. Available: http://www.nhi.gov.tw/resource/Webdata/Attach-15634-1- National%20Health%20Insurance%20in%20Taiwan%202010.pdf. Accessed 20 July 2012.
28. Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY et al. (2012) Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist 17: 970-977. doi:10.1634/theoncologist.2011-0411. PubMed: 22673633.
29. Green FL, Page DL, Fleming ID, Fritz AG, Balch CM et al. (2002) Liver including intrahepatic bile ducts, AJCC Cancer Staging Handbook. 6th ed. New York: Springer. pp. 131-144.
30. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a Clinical Comorbidity Index for Use with Icd-9-Cm Administrative Databases. J Clin Epidemiol 45: 613-619. doi:10.1016/0895-4356(92)90133-8. PubMed: 1607900.
31. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B et al. (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43: 1130-1139. doi:10.1097/01.mlr.0000182534.19832.83. PubMed: 16224307. (Pubitemid 41587600)
32. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L et al. (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210: 655-661. doi:10.1148/radiology.210.3. r99fe40655. PubMed: 10207464. (Pubitemid 29124024)
33. Edwards SJL, Lilford RJ, Braunholtz DA, Jackson JC, Hewison J et al. (1998) Ethical issues in the design and conduct of randomized controlled trials. Health Technol Asses 2: 1-132.
34. Kuo SH, Yang CH, Yu CJ, Hsu C, Cheng AL et al. (2005) Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials. Lung Cancer 48: 275-280. doi:10.1016/j.lungcan.2004.10.004. PubMed: 15829329.